oral sel. IDO1 dioxygenase inhibitor

100 mg QD, in I/O combo studies for cancer

acts on apo-IDO1 displacing heme co-factor

Mol. Cancer Ther., Dec. 9, 2020

BMS, Princeton, NJ / Flexus, San Carlos, CA

Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks